Table 4. Adverse effects reported in each arm after the pralidoxime chloride/placebo loading dose or during the first 3 d of the constant infusion.
| Adverse Effect | Loading dose (t = 20 min) | Constant infusion (t = 20 min to 72 h) | ||||
| Placebo | Pralidoxime | p-Value | Placebo | Pralidoxime | p-Value | |
| Tachycardia a , n (%) | 30/110 (27.3) | 61/115 (53.0) | <0.0001 | 54/111 (48.6) | 85/114 (74.6) | <0.0001 |
| Hypertension b , n (%) | 2/110 (1.8) | 27/115 (23.5) | <0.0001 | 16/111 (14.4) | 34/114 (29.8) | 0.005 |
| Headache, n (%) | 5/110 (4.5) | 7/115 (6.1) | 0.61 | 33/111 (29.7) | 36/114 (31.6) | 0.76 |
| Blurred vision, n (%) | 3/110 (2.7) | 8/115 (7.0) | 0.14 | 26/111 (23.4) | 40/114 (35.1) | 0.06 |
| Dizziness, n (%) | 8/110 (7.3) | 9/115 (7.8) | 0.88 | 35/111 (31.5) | 31/114 (27.2) | 0.48 |
| Nausea, n (%) | 12/110 (10.9) | 13/115 (11.3) | 0.93 | 33/111 (29.7) | 25/114 (21.9) | 0.18 |
| Vomiting, n (%) | 8/110 (7.3) | 21/115 (18.3) | 0.01 | 24/111 (21.6) | 26/114 (22.8) | 0.83 |
| Systolic BP, mmHg, mean (SD) | 116 (15.3) | 129 (27.6) | <0.0001 | ND | ND | |
| Diastolic BP, mmHg, mean (SD) | 74 (13.5) | 80 (20.2) | 0.015 | ND | ND | |
| Pulse, bpm, mean (SD) | 99 (20.1) | 113 (22.8) | <0.0001 | ND | ND | |
a
Tachycardia, HR>100 bpm.
b
Hypertension, systolic BP>159 and/or diastolic>99 mmHg.
ND, not done.